Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ACT therapy

- PMLiVE

Merck & Co picks Nike exec to be digital transformation leader

Cyber-security and customer focus will be key issues

- PMLiVE

Cancer care – the power of new technologies

With patient numbers set to soar, how can we make a difference?

- PMLiVE

BMS finds a new immunotherapy partner with $12m Compugen deal

Combination with novel antibody targeting PVRIG pathway

- PMLiVE

A look ahead to key trial readouts at ESMO

New combinations and novel mechanisms on show

- PMLiVE

RET rivals Loxo and Blueprint face off with early-stage data

No clear winner between RET inhibitor rivals

- PMLiVE

Chinese biotech’s global ambitions

BeiGene aims to be the first home-grown big biopharma

Eli Lilly HQ

Lilly gets EMA nod for Verzenio in breast cancer

And puts pressure on Pfizer’s market leading Ibrance and Novartis’ Kisqali

The dark side of direct-to-consumer genetic tests

Direct-to-consumer testing is an affordable way to better understand your DNA, but is this a leap forward in innovation or another layer clouding an already complex market? From anxious patients...

Blue Latitude Health

- PMLiVE

Daiichi-Sankyo takes rival to Roche’s Kadcyla into phase 3

Contender could offer potency without dose-limiting toxicities

- PMLiVE

J&J files ‘breakthrough’ bladder cancer drug in US

Needed as most patients don't respond to checkpoint inhibitors

- PMLiVE

AZ nabs US approval for new leukaemia drug Lumoxiti

Adds to firm's growing oncology franchise

- PMLiVE

MSD wins key EU approval for Keytruda, Alimta combo

Decision keeps Keytruda well ahead of rival Tecentriq

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links